Joanna Mika

List of Publications by Year
in descending order

122 papers	5,604 citations	66315 42 h-index	88593 70 g-index
123 all docs	123 docs citations	123 times ranked	5814 citing authors

#	Article	IF	Citations
1	Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 2019, 20, 1451.	1.8	414
2	Importance of glial activation in neuropathic pain. European Journal of Pharmacology, 2013, 716, 106-119.	1.7	362
3	Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. European Journal of Pharmacology, 2007, 560, 142-149.	1.7	211
4	Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. European Journal of Pharmacology, 2009, 623, 65-72.	1.7	160
5	Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain, Behavior, and Immunity, 2009, 23, 75-84.	2.0	160
6	Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochemical and Biophysical Research Communications, 2006, 350, 238-243.	1.0	147
7	Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacological Reports, 2008, 60, 297-307.	1.5	147
8	Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain. Current Medicinal Chemistry, 2016, 23, 2908-2928.	1.2	143
9	Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. European Journal of Pharmacology, 1999, 367, 189-196.	1.7	123
10	Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain. Pain, 2008, 139, 117-126.	2.0	110
11	Prenatal stress is a vulnerability factor for altered morphology and biological activity of microglia cells. Frontiers in Cellular Neuroscience, 2015, 9, 82.	1.8	108
12	The glutamatergic system as a target for neuropathic pain relief. Experimental Physiology, 2013, 98, 372-384.	0.9	100
13	Neuronal and immunological basis of action of antidepressants in chronic pain â€“ clinical and experimental studies. Pharmacological Reports, 2013, 65, 1611-1621.	1.5	91
14	Maraviroc reduces neuropathic pain through polarization of microglia and astroglia â€“ Evidence from inÂvivo and inÂvitro studies. Neuropharmacology, 2016, 108, 207-219.	2.0	91
15	Interleukin-1alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain, 2008, 138, 587-597.	2.0	88
16	Targeting the NLRP3 Inflammasome-Related Pathways via Tianeptine Treatment-Suppressed Microglia Polarization to the M1 Phenotype in Lipopolysaccharide-Stimulated Cultures. International Journal of Molecular Sciences, 2018, 19, 1965.	1.8	84
17	Anandamide, Acting via<i>CB2</i>Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plasticity, 2015, 2015, 1-10.	1.0	83
18	The role of Î´-opioid receptor subtypes in neuropathic pain. European Journal of Pharmacology, 2001, 415, 31-37.	1.7	82

#	Article	IF	Citations
19	Effects of selective and non-selective inhibitors of nitric oxide synthase on morphine- and endomorphin-1-induced analgesia in acute and neuropathic pain in rats. Neuropharmacology, 2013, 75, 445-457.	2.0	82
20	Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochemistry International, 2007, 50, 281-290.	1.9	81
21	Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. Journal of Neuroimmunology, 2014, 277, 57-66.	1.1	81
22	Parthenolide Relieves Pain and Promotes M2 Microglia/Macrophage Polarization in Rat Model of Neuropathy. Neural Plasticity, 2015, 2015, 1-15.	1.0	80
23	Mechanisms and pharmacology of diabetic neuropathy â€“ experimental and clinical studies. Pharmacological Reports, 2013, 65, 1601-1610.	1.5	79
24	Blockade of Toll-Like Receptors (TLR2, TLR4) Attenuates Pain and Potentiates Buprenorphine Analgesia in a Rat Neuropathic Pain Model. Neural Plasticity, 2016, 2016, 1-12.	1.0	77
25	Delta-Opioid Receptor Analgesia Is Independent of Microglial Activation in a Rat Model of Neuropathic Pain. PLoS ONE, 2014, 9, e104420.	1.1	74
26	The role of nociceptin and dynorphin in chronic pain: Implications of neuroâ€“glial interaction. Neuropeptides, 2011, 45, 247-261.	0.9	73
27	Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Pronociceptive Interleukin Release in a Rat Model. Frontiers in Pharmacology, 2017, 8, 48.	1.6	69
28	Blockade of IL-18 signaling diminished neuropathic pain and enhanced the efficacy of morphine and buprenorphine. Molecular and Cellular Neurosciences, 2016, 71, 114-124.	1.0	65
29	Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 68-78.	2.5	60
30	Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain. European Journal of Pharmacology, 2016, 791, 377-388.	1.7	57
31	Chronic morphine increases biosynthesis of nitric oxide synthase in the rat spinal cord. NeuroReport, 1997, 8, 2743-2747.	0.6	56
32	Inhibition of intracellular signaling pathways NF-Î°B and MEK1/2 attenuates neuropathic pain development and enhances morphine analgesia. Pharmacological Reports, 2014, 66, 845-851.	1.5	56
33	Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy. Journal of Neuroimmunology, 2013, 262, 35-45.	1.1	54
34	Direct and indirect pharmacological modulation of CCL2/CCR2 pathway results in attenuation of neuropathic pain â€” In vivo and in vitro evidence. Journal of Neuroimmunology, 2016, 297, 9-19.	1.1	54
35	The Effects of Local Pentoxifylline and Propentofylline Treatment on Formalin-Induced Pain and Tumor Necrosis Factor-?? Messenger RNA Levels in the Inflamed Tissue of the Rat Paw. Anesthesia and Analgesia, 2004, 98, 1566-1573.	1.1	52
36	The RS504393 Influences the Level of Nociceptive Factors and Enhances Opioid Analgesic Potency in Neuropathic Rats. Journal of NeuroImmune Pharmacology, 2017, 12, 402-419.	2.1	52

#	Article	IF	Citations
37	Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model. Neuropharmacology, 2016, 102, 80-91.	2.0	49
38	Involvement of Macrophage Inflammatory Protein-1 Family Members in the Development of Diabetic Neuropathy and Their Contribution to Effectiveness of Morphine. Frontiers in Immunology, 2018, 9, 494.	2.2	48
39	IL-1 receptor antagonist improves morphine and buprenorphine efficacy in a rat neuropathic pain model. European Journal of Pharmacology, 2015, 764, 240-248.	1.7	47
40	Minocycline prevents dynorphin-induced neurotoxicity during neuropathic pain in rats. Neuropharmacology, 2014, 86, 301-310.	2.0	46
41	Chemokines CCL2 and CCL7, but not CCL12, play a significant role in the development of pain-related behavior and opioid-induced analgesia. Cytokine, 2019, 119, 202-213.	1.4	46
42	Comparison of the Expression Changes after Botulinum Toxin Type A and Minocycline Administration in Lipopolysaccharide-Stimulated Rat Microglial and Astroglial Cultures. Frontiers in Cellular and Infection Microbiology, 2017, 7, 141.	1.8	44
43	PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of Neuropathy. PLoS ONE, 2015, 10, e0138583.	1.1	44
44	The importance of chemokines in neuropathic pain development and opioid analgesic potency. Pharmacological Reports, 2018, 70, 821-830.	1.5	42
45	Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model. Frontiers in Pharmacology, 2018, 9, 724.	1.6	41
46	Expression Profiling of Genes Modulated by Minocycline in a Rat Model of Neuropathic Pain. Molecular Pain, 2014, 10, 1744-8069-10-47.	1.0	40
47	Microglial Inhibition Influences XCL1/XCR1 Expression and Causes Analgesic Effects in a Mouse Model of Diabetic Neuropathy. Anesthesiology, 2016, 125, 573-589.	1.3	37
48	Pharmacological blockade of CXCR3 by (Â±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3418-3437.	1.8	37
49	Bifunctional Peptide-Based Opioid Agonistâ€"Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. Journal of Medicinal Chemistry, 2016, 59, 3777-3792.	2.9	36
50	Antinociceptive effects of novel histamine H₃ and H₄ receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse. British Journal of Pharmacology, 2018, 175, 2897-2910.	2.7	36
51	Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain. Pain, 2009, 147, 175-186.	2.0	35
52	Transcranial direct current stimulation (tDCS) and its influence on analgesics effectiveness in patients suffering from migraine headache. Pharmacological Reports, 2017, 69, 714-721.	1.5	35
53	Botulinum Toxin Type Aâ€"A Modulator of Spinal Neuronâ€"Glia Interactions under Neuropathic Pain Conditions. Toxins, 2018, 10, 145.	1.5	35
54	The Role of Some Chemokines from the CXC Subfamily in a Mouse Model of Diabetic Neuropathy. Journal of Diabetes Research, 2015, 2015, 1-13.	1.0	32

#	Article	IF	Citations
55	Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target â€“ Evidence from a mouse diabetic neuropathy model. International Immunopharmacology, 2017, 52, 261-271.	1.7	31
56	Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice. ACS Chemical Neuroscience, 2017, 8, 2315-2324.	1.7	30
57	The influence of microglia activation on the efficacy of amitriptyline, doxepin, milnacipran, venlafaxine and fluoxetine in a rat model of neuropathic pain. European Journal of Pharmacology, 2015, 749, 115-123.	1.7	29
58	Neuropathic Pain Dysregulates Gene Expression of the Forebrain Opioid and Dopamine Systems. Neurotoxicity Research, 2020, 37, 800-814.	1.3	29
59	Morphine and endomorphin-1 differently influence pronociceptin/orphanin FQ system in neuropathic rats. Pharmacology Biochemistry and Behavior, 2004, 78, 171-178.	1.3	28
60	Minocycline Enhances the Effectiveness of Nociceptin/Orphanin FQ during Neuropathic Pain. BioMed Research International, 2014, 2014, 1-12.	0.9	28
61	The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain. Immunology, 2020, 159, 413-428.	2.0	28
62	Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist â€“ Neurokinin-1 antagonist peptidomimetics. European Journal of Medicinal Chemistry, 2015, 92, 64-77.	2.6	27
63	Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury. Frontiers in Immunology, 2019, 10, 2198.	2.2	27
64	Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Painâ€"Narrative Review. Pharmaceutics, 2021, 13, 450.	2.0	27
65	Relationship of pronociceptin/orphanin FQ and the nociceptin receptor ORL1 with substance P and calcitonin gene-related peptide expression in dorsal root ganglion of the rat. Neuroscience Letters, 2003, 348, 190-194.	1.0	26
66	The CCL2/CCL7/CCL12/CCR2 pathway is substantially and persistently upregulated in mice after traumatic brain injury, and CCL2 modulates the complement system in microglia. Molecular and Cellular Probes, 2020, 54, 101671.	0.9	26
67	Peripheral Mechanisms of Neuropathic Painâ€"The Role of Neuronal and Non-Neuronal Interactions and Their Implications for Topical Treatment of Neuropathic Pain. Pharmaceuticals, 2021, 14, 77.	1.7	26
68	Treatment with a carbon monoxide-releasing molecule (CORM-2) inhibits neuropathic pain and enhances opioid effectiveness in rats. Pharmacological Reports, 2016, 68, 206-213.	1.5	25
69	Biphalin, a Dimeric Enkephalin, Alleviates LPS-Induced Activation in Rat Primary Microglial Cultures in Opioid Receptor-Dependent and Receptor-Independent Manners. Neural Plasticity, 2017, 2017, 1-19.	1.0	24
70	Effects of chronic doxepin and amitriptyline administration in naÃ¯ve mice and in neuropathic pain mice model. Neuroscience, 2015, 294, 38-50.	1.1	23
71	Fluorinated indole-imidazole conjugates: Selective orally bioavailable 5-HT7 receptor low-basicity agonists, potential neuropathic painkillers. European Journal of Medicinal Chemistry, 2019, 170, 261-275.	2.6	22
72	Changes in macrophage inflammatory protein-1 (MIP-1) family members expression induced by traumatic brain injury in mice. Immunobiology, 2020, 225, 151911.	0.8	22

#	Article	IF	Citations
73	The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives. International Journal of Molecular Sciences, 2021, 22, 11055.	1.8	22
74	Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics. ACS Medicinal Chemistry Letters, 2015, 6, 1209-1214.	1.3	20
75	Perioperative Immunosuppression and Risk of Cancer Progression: The Impact of Opioids on Pain Management. Pain Research and Management, 2018, 2018, 1-8.	0.7	20
76	Kynurenic acid and zaprinast diminished CXCL17-evoked pain-related behaviour and enhanced morphine analgesia in a mouse neuropathic pain model. Pharmacological Reports, 2019, 71, 139-148.	1.5	20
77	Mirogabalinâ€"A Novel Selective Ligand for the Î±2Î´ Calcium Channel Subunit. Pharmaceuticals, 2021, 14, 112.	1.7	20
78	Non-invasive transcutaneous Supraorbital Neurostimulation (tSNS) using Cefaly Â® device in prevention of primary headaches. Neurologia I Neurochirurgia Polska, 2017, 51, 127-134.	0.6	19
79	Lipopolysaccharide from <i>Rhodobacter sphaeroides</i> (TLR4 antagonist) attenuates hypersensitivity and modulates nociceptive factors. Pharmaceutical Biology, 2018, 56, 275-286.	1.3	18
80	Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. Pharmacological Reports, 2016, 68, 1069-1075.	1.5	17
81	Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy. Frontiers in Immunology, 2020, 11, 615327.	2.2	17
82	Age-dependent changes in thymuses in the European common frog,Rana temporaria. The Journal of Experimental Zoology, 1995, 273, 451-460.	1.4	16
83	CCR4 Antagonist (C021) Administration Diminishes Hypersensitivity and Enhances the Analgesic Potency of Morphine and Buprenorphine in a Mouse Model of Neuropathic Pain. Frontiers in Immunology, 2020, 11, 1241.	2.2	16
84	CCR4 antagonist (C021) influences the level of nociceptive factors and enhances the analgesic potency of morphine in a rat model of neuropathic pain. European Journal of Pharmacology, 2020, 880, 173166.	1.7	16
85	Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses. International Immunopharmacology, 2020, 84, 106540.	1.7	16
86	Blockade of CC Chemokine Receptor Type 3 Diminishes Pain and Enhances Opioid Analgesic Potency in a Model of Neuropathic Pain. Frontiers in Immunology, 2021, 12, 781310.	2.2	15
87	Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain. Neuropharmacology, 2020, 178, 108232.	2.0	14
88	Evidence for Fos involvement in the regulation of proenkephalin and prodynorphin gene expression in the rat hippocampus. Molecular Brain Research, 1998, 54, 243-251.	2.5	13
89	Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Modelâ€"In Vivo and In Vitro Study. International Journal of Molecular Sciences, 2021, 22, 11074.	1.8	13
90	Tapentadol â€" A representative of a new class of MOR-NRI analgesics. Pharmacological Reports, 2018, 70, 812-820.	1.5	12

#	Article	IF	Citations
91	Zaprinast diminished pain and enhanced opioid analgesia in a rat neuropathic pain model. European Journal of Pharmacology, 2018, 839, 21-32.	1.7	12
92	Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic Pain Model. Neuroscience, 2018, 390, 293-302.	1.1	12
93	Long pentraxin PTX3 is upregulated systemically and centrally after experimental neurotrauma, but its depletion leaves unaltered sensorimotor deficits or histopathology. Scientific Reports, 2021, 11, 9616.	1.6	12
94	Season-specific thymic architecture in the frog, Rana temporaria: Sem studies. Developmental and Comparative Immunology, 1996, 20, 129-137.	1.0	11
95	Bifunctional opioid/nociceptin hybrid KGNOP1 effectively attenuates pain-related behaviour in a rat model of neuropathy. European Journal of Pharmaceutical Sciences, 2017, 104, 221-229.	1.9	11
96	Involvement of microglial cells in the antinociceptive effects of metamizol in a mouse model of neuropathic pain. Pharmacology Biochemistry and Behavior, 2018, 175, 77-88.	1.3	11
97	Immunoglobulin G4-Related Disease (IgG4-RD) in the Orbit: Mucosa-Associated Lymphoid Tissue (MALT)-Type Lymphomas. Medical Science Monitor, 2015, 21, 1043-1050.	0.5	11
98	Blockade of CCR4 Diminishes Hypersensitivity and Enhances Opioid Analgesia â€" Evidence from a Mouse Model of Diabetic Neuropathy. Neuroscience, 2020, 441, 77-92.	1.1	10
99	Novel bifunctional hybrid compounds designed to enhance the effects of opioids and antagonize the pronociceptive effects of nonopioid peptides as potent analgesics in a rat model of neuropathic pain. Pain, 2021, 162, 432-445.	2.0	9
100	Analysis of the Dorsal Spinal Cord Synaptic Architecture by Combined Proteome Analysis and in Situ Hybridization. Journal of Proteome Research, 2005, 4, 238-249.	1.8	8
101	Metamizole relieves pain by influencing cytokine levels in dorsal root ganglia in a rat model of neuropathic pain. Pharmacological Reports, 2020, 72, 1310-1322.	1.5	8
102	Initiators of Classical and Lectin Complement Pathways Are Differently Engaged after Traumatic Brain Injuryâ€"Time-Dependent Changes in the Cortex, Striatum, Thalamus and Hippocampus in a Mouse Model. International Journal of Molecular Sciences, 2021, 22, 45.	1.8	8
103	Original article IgG4-related inflammatory orbital pseudotumors â€" a retrospective case series. Folia Neuropathologica, 2015, 2, 111-120.	0.5	7
104	Traumatic brain injury in mice induces changes in the expression of the XCL1/XCR1 and XCL1/ITGA9 axes. Pharmacological Reports, 2020, 72, 1579-1592.	1.5	7
105	Analgesic effects of antidepressants alone and after their local co-administration with morphine in a rat model of neuropathic pain. Pharmacological Reports, 2014, 66, 459-465.	1.5	6
106	Nitric oxide modulates tapentadol antinociceptive tolerance and physical dependence. European Journal of Pharmacology, 2021, 907, 174245.	1.7	5
107	Rola chemokin w bÃ³lu neuropatycznym. BÃ³l, 2014, 15, 19-35.	0.1	4
108	Spontaneous cerebrospinal fluid leak at the clivus. Wideochirurgia I Inne Techniki Maloinwazyjne, 2015, 4, 593-599.	0.3	3

#	Article	IF	Citations
109	Characteristics, diagnosis and therapeutic strategies for IgG4-related orbital disease. Pharmacological Reports, 2016, 68, 507-513.	1.5	3
110	Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain. Pharmaceuticals, 2022, 15, 88.	1.7	3
111	Dataset of botulinum toxin A influence on interleukins under neuropathy. Data in Brief, 2016, 9, 1020-1023.	0.5	2
112	Dataset of (Â±)-NBI-74330 (CXCR3 antagonist) influence on chemokines under neuropathic pain. Data in Brief, 2018, 21, 1145-1150.	0.5	2
113	Hybrid peptidomimetics for the use in neuropathicpain. , 0, , .		2
114	Rola cytokin z rodziny interleukiny-1 w transmisji nocyceptywnej. BÃ³l, 2016, 15, 39-47.	0.1	2
115	Plasticity of thymuses of ectothermic vertebrates. Trends in Immunology, 1996, 17, 442.	7.5	1
116	A new potential mechanism of action of tianeptine â€“ the effect on microglial cell activation. SpringerPlus, 2015, 4, .	1.2	1
117	Effects of ORL1 Receptor Agonists and Antagonists in Nociception. Journal of Neuropathic Pain & Symptom Palliation, 2006, 2, 29-44.	0.1	0
118	Preclinical Cancer Pain Models. , 2013, , 71-93.		0
119	Castleman's disease of the neck - case report. , 2015, 4, 40-43.		0
120	Marawirok jako potencjalny lek stosowany w terapii bÃ³lu neuropatycznego â€“ dowody z badaÅ„ podstawowych. BÃ³l, 2015, 16, 31-36.	0.1	0
121	Zatokowy bÃ³l twarzoczaszki â€“ trudnoÅ›ci diagnostyczne w rÃ³Å¼nicowaniu. BÃ³l, 2016, 15, 48-51.	0.1	0
122	Apelin as a nociceptive processes regulator. BÃ³l, 2019, 19, 1-9.	0.1	0